Van ECK Associates Corp Has $11.96 Million Position in Charles River Laboratories International, Inc. (NYSE:CRL)

Van ECK Associates Corp boosted its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 4.1% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 57,906 shares of the medical research company’s stock after buying an additional 2,269 shares during the period. Van ECK Associates Corp’s holdings in Charles River Laboratories International were worth $11,962,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of CRL. Headlands Technologies LLC acquired a new position in Charles River Laboratories International in the first quarter valued at approximately $41,000. VisionPoint Advisory Group LLC lifted its holdings in Charles River Laboratories International by 45.1% in the fourth quarter. VisionPoint Advisory Group LLC now owns 209 shares of the medical research company’s stock valued at $49,000 after buying an additional 65 shares during the period. Brown Brothers Harriman & Co. raised its holdings in Charles River Laboratories International by 76.0% in the fourth quarter. Brown Brothers Harriman & Co. now owns 220 shares of the medical research company’s stock worth $52,000 after purchasing an additional 95 shares during the period. Whittier Trust Co. of Nevada Inc. raised its holdings in Charles River Laboratories International by 219.3% in the second quarter. Whittier Trust Co. of Nevada Inc. now owns 281 shares of the medical research company’s stock worth $58,000 after purchasing an additional 193 shares during the period. Finally, Concord Wealth Partners raised its holdings in Charles River Laboratories International by 362.5% in the first quarter. Concord Wealth Partners now owns 259 shares of the medical research company’s stock worth $70,000 after purchasing an additional 203 shares during the period. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the stock. JPMorgan Chase & Co. lowered shares of Charles River Laboratories International from an “overweight” rating to a “neutral” rating and cut their target price for the stock from $270.00 to $205.00 in a report on Thursday, August 8th. Evercore ISI cut their target price on shares of Charles River Laboratories International from $265.00 to $225.00 and set an “outperform” rating on the stock in a report on Thursday, August 8th. UBS Group cut their target price on shares of Charles River Laboratories International from $290.00 to $240.00 and set a “buy” rating on the stock in a report on Thursday, August 8th. Argus reiterated a “hold” rating on shares of Charles River Laboratories International in a report on Friday, June 28th. Finally, Baird R W lowered shares of Charles River Laboratories International from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 8th. Ten equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $231.00.

Charles River Laboratories International Stock Down 0.8 %

Charles River Laboratories International stock opened at $197.75 on Monday. The company has a market cap of $10.21 billion, a P/E ratio of 23.26, a price-to-earnings-growth ratio of 3.97 and a beta of 1.38. Charles River Laboratories International, Inc. has a 1-year low of $161.65 and a 1-year high of $275.00. The company has a fifty day simple moving average of $211.77 and a 200 day simple moving average of $229.26. The company has a current ratio of 1.58, a quick ratio of 1.21 and a debt-to-equity ratio of 0.65.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Wednesday, August 7th. The medical research company reported $2.80 earnings per share for the quarter, beating analysts’ consensus estimates of $2.39 by $0.41. The business had revenue of $1.03 billion during the quarter, compared to the consensus estimate of $1.03 billion. Charles River Laboratories International had a net margin of 10.83% and a return on equity of 14.96%. Research analysts anticipate that Charles River Laboratories International, Inc. will post 10.02 earnings per share for the current fiscal year.

Charles River Laboratories International declared that its board has authorized a share repurchase plan on Wednesday, August 7th that allows the company to repurchase $1.00 billion in shares. This repurchase authorization allows the medical research company to reacquire up to 9.6% of its shares through open market purchases. Shares repurchase plans are usually an indication that the company’s management believes its shares are undervalued.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).